



March 17, 2017  
NRC:17:013

U.S. Nuclear Regulatory Commission  
Document Control Desk  
11555 Rockville Pike  
Rockville, MD 20852

PROJ 0728

**Replacement Publication of EMF-2328PA, Revision 0, Supplement 1PA, Revision 0, "PWR Small Break LOCA Evaluation Model, S-RELAP5 Based"**


In Reference 1, the NRC accepted topical report EMF-2328(P)(A), Revision 0, Supplement 1, Revision 0, "PWR (Pressurized Water Reactor) Small Break LOCA (Loss-of-Coolant Accident) Evaluation Model, S-RELAP5 Based" for referencing in license applications. The non-proprietary version of the final safety evaluation was sent to AREVA, Inc. (AREVA) in Reference 2. The NRC requested that AREVA Inc. publish a proprietary and non-proprietary version of the report.

As explained in References 1 and 2, the enclosed Safety Evaluation (SE) is a revision of the SE provided in Reference 3. The enclosed report is a replacement for that submitted in Reference 4.

Proprietary and non-proprietary versions of the replacement report are enclosed. The published report is constructed in accordance with guidance provided on the NRC website. As required by 10 CFR 2.390(b) an affidavit is enclosed to support the withholding of the proprietary version of the report from public disclosure.

If you have any questions related to this submittal, please contact Mr. Morris Byram, Licensing Manager, by telephone at (434) 832-4665, or by e-mail at [Morris.Byram@areva.com](mailto:Morris.Byram@areva.com).

Sincerely,



Gary Peters, Director  
Licensing & Regulatory Affairs  
AREVA Inc.

cc: J. G. Rowley  
Project 728

YGDI  
NRR

**AREVA INC.**

3315 Old Forest Road, Lynchburg, VA 24501  
Tel.: 434 832 3000 - [www.areva.com](http://www.areva.com)

- Ref. 1: Letter, Kevin Hsueh (NRR) to Gary Peters (AREVA Inc.), "Revised Final Safety Evaluation by the Office of Nuclear Reactor Regulation for Topical Report EMF-2328(P)(A), Revision 0, Supplement 1, Revision 0, 'PWR (Pressurized Water Reactor) Small Break LOCA (Loss-of-Coolant Accident) Evaluation Model, S-RELAP5 Based'," December 13, 2016.
- Ref. 2: Letter, Kevin Hsueh (NRR) to Gary Peters (AREVA Inc.), "Revised Final Safety Evaluation by the Office of Nuclear Reactor Regulation for Topical Report EMF-2328(P)(A), Revision 0, Supplement 1, Revision 0, 'PWR Small Break LOCA Evaluation Model, S-RELAP5 Based'," CFC No. MF7268, February 1, 2017.
- Ref. 3: Letter, Mirela Gavrilas (NRR) to Pedro Salas (AREVA Inc.), "Final Safety Evaluation by the Office of Nuclear Reactor Regulation for Topical Report EMF-2328(P)(A), Revision 0, Supplement 1, Revision 0, 'PWR (Pressurized Water Reactor) Small Break LOCA (Loss-of-Coolant Accident) Evaluation Model, S-RELAP5 Based'," September 1, 2015.
- Ref.4: Letter, Gayle Elliott (AREVA Inc.) to Document Control Desk (NRC), "Publication of EMF-2328PA, Revision 0, Supplement 1PA, Revision 0, 'PWR Small Break LOCA Evaluation Model, S-RELAP5 Based'," December 15, 2015.

#### Enclosures

1. EMF-2328(P)(A), Revision 0, Supplement 1(P)(A), Revision 0, "PWR Small Break LOCA Evaluation Model, S-RELAP5 Based"
2. EMF-2328(NP)(A), Revision 0, Supplement 1(NP)(A), Revision 0, "PWR Small Break LOCA Evaluation Model, S-RELAP5 Based"
3. Notarized Affidavit



requested qualifies under 10 CFR 2.390(a)(4) "Trade secrets and commercial or financial information."

6. The following criteria are customarily applied by AREVA to determine whether information should be classified as proprietary:

- (a) The information reveals details of AREVA's research and development plans and programs or their results.
- (b) Use of the information by a competitor would permit the competitor to significantly reduce its expenditures, in time or resources, to design, produce, or market a similar product or service.
- (c) The information includes test data or analytical techniques concerning a process, methodology, or component, the application of which results in a competitive advantage for AREVA.
- (d) The information reveals certain distinguishing aspects of a process, methodology, or component, the exclusive use of which provides a competitive advantage for AREVA in product optimization or marketability.
- (e) The information is vital to a competitive advantage held by AREVA, would be helpful to competitors to AREVA, and would likely cause substantial harm to the competitive position of AREVA.

The information in this Document is considered proprietary for the reasons set forth in paragraphs 6(c) and 6(d) above.

7. In accordance with AREVA's policies governing the protection and control of information, proprietary information contained in this Document has been made available, on a limited basis, to others outside AREVA only as required and under suitable agreement providing for nondisclosure and limited use of the information.

8. AREVA policy requires that proprietary information be kept in a secured file or area and distributed on a need-to-know basis.

9. The foregoing statements are true and correct to the best of my knowledge, information, and belief.

Marie E. Bayne

SUBSCRIBED before me this 16<sup>th</sup>  
day of March, 2017.

Sherry L. McFaden

Sherry L. McFaden  
NOTARY PUBLIC, COMMONWEALTH OF VIRGINIA  
MY COMMISSION EXPIRES: 10/31/18  
Reg. # 7079129

